Substituted amino isoxazoline derivatives and their use as...

Details Substituted amino isoxazoline derivatives and their use as... Substituted amino isoxazoline derivatives and their use as...

2007-09-04

2007-09-04

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S229500, C514S232500, C514S253030, C514S254040, C514S293000, C514S321000, C540S599000, C540S603000, C544S099000, C544S137000, C544S361000, C544S368000, C546S083000, C546S198000

Reexamination Certificate

active

10510220

ABSTRACT:
The invention concerns substituted amino isoxazoline derivatives, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisozazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with primary, secondary and/or tertiary amino groups, according to Formula (I)wherein X=CH2, N—R7, S or O, R1, R2and R3are certain specific substituents, with the proviso that at least one of R1and R2is an amino radical of formula N—R10R11wherein R10and R11are each a variety of radicals, Pir is an optionally substituted piperidyl or piperazyl radical and R3represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with additional α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compounds according to the invention are also suitable for treating depression, anxiety and body weight disorders. The invention also relates to novel combination of substituted amino isoxazoline derivatives according to the invention with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

REFERENCES:
patent: 2005/0256119 (2005-11-01), Andres-Gil et al.
patent: 2006/0122167 (2006-06-01), Andres-Gil et al.
patent: 0361577 (1993-05-01), None
patent: 0885883 (1998-12-01), None
patent: WO97/25317 (1997-07-01), None
patent: WO 02066484 (2002-08-01), None
Crow et al.Expert Opin.Investig.Drugs, vol. 12(3), p. 491-499 (2003).
O'Neil M.J., “The Merck Index, thirteenth edition,” 2001, Merck & Co., Inc., pp. 741, monography 4211.
Stella, V.J. et al., “Prodrugs Do They Have Advantages in Clinical Practice?,” Drugs 29, 1985, pp. 455-473.
PCT Search Report dated Jul. 31, 2003 for PCT/EP03/03245.

Affiliated with

Also associated with

Rating

Substituted amino isoxazoline derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted amino isoxazoline derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted amino isoxazoline derivatives and their use as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3759953